Express News | Autolus Therapeutics Says It Will Reveal Three Abstracts To Be Presented At European Hematology Association (EHA) Congress

BenzingaJun 14 07:14 ET

Autolus Therapeutics to Present Three Clinical Data Updates on Obecabtagene Autoleucel (Obe-cel) in Relapsed/refractory (R/r) B-Cell Acute Lymphoblastic Leukemia (ALL) Patients at the 2024 European Hematology Association (EHA) Congress

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces three abstracts to be

GlobeNewswireJun 14 07:00 ET

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading

European equities traded in the US as American depositary receipts were moving sharply higher late Wednesday morning, rising 1.59% to 1,445.87 on the S&P Europe Select ADR Index. From continental Euro

MT NewswiresJun 12 11:20 ET

European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading

European equities traded in the US as American depositary receipts were trending sharply lower late Tuesday morning, falling 1.34% to 1,420.05 on the S&P Europe Select ADR Index. From continental Euro

MT NewswiresJun 11 11:11 ET

Analysts' Top Healthcare Picks: Autolus Therapeutics (AUTL), Affimed (AFMD)

TipRanksJun 3 06:20 ET

Autolus Therapeutics Presents Longer-term Follow-up and Additional Data Analysis of Pivotal Phase 2 FELIX Study of Obe-cel for Adult R/r B-ALL in an Oral Presentation at ASCO

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem cell transplant

GlobeNewswireMay 31 08:00 ET